Related MeSH Hierarchy (4)
Diseases [C] » Nervous System Diseases [C10] » Autoimmune Diseases of the Nervous System » Demyelinating Autoimmune Diseases, CNS
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Leukoencephalopathies » Demyelinating Autoimmune Diseases, CNS
Diseases [C] » Nervous System Diseases [C10] » Demyelinating Diseases » Demyelinating Autoimmune Diseases, CNS
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Autoimmune Diseases of the Nervous System » Demyelinating Autoimmune Diseases, CNS
Description
Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens. MeSH
Hierarchy View
Subtype Terms (7)
Diffuse Cerebral Sclerosis of Schilder
1 experimental drug
Leukoencephalitis, Acute Hemorrhagic
Multiple Sclerosis
329 drugs (172 approved, 157 experimental)
Myelitis, Transverse
7 drugs (5 approved, 2 experimental)
Neuromyelitis Optica
42 drugs (29 approved, 13 experimental)
Phase 4 Indicated Drugs (1)
Organization Involved with Phase 4 Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
